Thursday, June 11, 2026

Patent directory · USPTO A61K / A61P

Browse patents

Browse 30,257 pharma-relevant patents (US A61K/A61P) linked to tracked companies, drugs, and pipeline programs.

Patents indexed 30,257
Companies 1,769
Drugs linked 4,797

Quick answer

NovaPharmaNews indexes 30,257 US pharmaceutical patents from USPTO PatentsView (CPC A61K/A61P), cross-linked to company assignees, drug INN profiles, and pipeline programs. Search by patent number, applicant, title, or CPC code — or use facet hubs for expiring patents, assignees, and therapeutic areas.

Patent results

Page 84 of 1,261
  1. US 12133914

    Hydrocortisone oral liquid formulations

    Eton Pharmaceuticals, Inc. · Granted Nov 5, 2024 · Expires Oct 31, 2044

    granted
  2. US 12134610

    Somatostatin subtype-2 receptor (SST2R) targeted therapeutics and uses thereof

    CRINETICS PHARMACEUTICALS, INC. · Granted Nov 5, 2024 · Expires Oct 31, 2044

    granted
  3. US 12134642

    Antibodies binding to α7β1 integrin antibodies and compositions thereof

    Pliant Therapeutics, Inc. · Granted Nov 5, 2024 · Expires Oct 31, 2044

    granted
  4. US 12133840

    Halogenated xanthene composition and method for treating hematologic cancers

    Provectus Pharmatech, Inc. · Granted Nov 5, 2024 · Expires Oct 31, 2044

    granted
  5. US 12134631

    Hydrophilic linkers for antibody drug conjugates

    REGENERON PHARMACEUTICALS, INC. · Granted Nov 5, 2024 · Expires Oct 31, 2044

    granted
  6. US 12134648

    Dual specificity antibodies to human PD-L1 and PD-L2 and methods of use therefor

    The Board of Regents of the University of Texas System · Granted Nov 5, 2024 · Expires Oct 31, 2044

    granted
  7. US 12134650

    Compositions targeting GABRA2 and methods for diagnosis and treatment of cancer

    TEL HASHOMER MEDICAL RESEARCH INFRASTRUCTURE AND SERVICES LTD. · Granted Nov 5, 2024 · Expires Oct 31, 2044

    granted
  8. US 12133890

    Antigen-binding polypeptide targeting B7H3 and application thereof

    NINGBO T-MAXIMUM BIOPHARMACEUTICALS CO., LTD. · Granted Nov 5, 2024 · Expires Oct 31, 2044

    granted
  9. US 12133853

    Pyruvate kinase activators for use in treating blood disorders

    Agios Pharmaceuticals, Inc. · Granted Nov 5, 2024 · Expires Oct 31, 2044

    granted
  10. US 12133831

    Kits for preparing and delivering purified corticotropin

    ANI Pharmaceuticals, Inc. · Granted Nov 5, 2024 · Expires Oct 31, 2044

    granted
  11. US 12133924

    Compositions and methods for organ specific delivery of nucleic acids

    The Board of Regents of the University of Texas System · Granted Nov 5, 2024 · Expires Oct 31, 2044

    granted
  12. WO 2024223388

    COMPLEXES CRISTALLINS ENTRE LA VELAGLIFLOZINE ET DES AGENTS DE FORMATION DE CO-CRISTAUX SÉLECTIONNÉS, LEURS PROCÉDÉS DE PRÉPARATION ET LEUR UTILISATION POUR LA PRÉPARATION DE MÉDICAMENTS

    BOEHRINGER INGELHEIM VETMEDICA GMBH [DE] · Granted Oct 31, 2024 · Expires Oct 26, 2044

    granted
  13. US 12129469

    Modified short interfering nucleic acid (siNA) molecules and uses thereof

    Aligos Therapeutics, Inc. · Granted Oct 29, 2024 · Expires Oct 24, 2044

    granted
  14. US 12129262

    CDK inhibitors and their use as pharmaceuticals

    Prelude Therapeutics, Incorporated · Granted Oct 29, 2024 · Expires Oct 24, 2044

    granted
  15. US 12128090

    Methods of prophylactic treatment using recombinant VWF (rVWF)

    Takeda Pharmaceutical Company Limited · Granted Oct 29, 2024 · Expires Oct 24, 2044

    granted
  16. US 12128015

    APE/REF1 inhibitors for the treatment of cancer

    The Regents of the University of California · Granted Oct 29, 2024 · Expires Oct 24, 2044

    granted
  17. US 12128036

    Compositions and methods for storage stable ophthalmic drugs

    LENZ THERAPEUTICS OPERATIONS, INC. · Granted Oct 29, 2024 · Expires Oct 24, 2044

    granted
  18. US 12128058

    Multi-substituent psilocybin derivatives and methods of using

    Enveric Biosciences Canada Inc. · Granted Oct 29, 2024 · Expires Oct 24, 2044

    granted
  19. US 12129471

    Materials and methods for treatment of human genetic diseases including hemoglobinopathies

    Vertex Pharmaceuticals Incorporated · Granted Oct 29, 2024 · Expires Oct 24, 2044

    granted
  20. US 12129476

    Methods for measuring the potency of AADC viral vectors

    VOYAGER THERAPEUTICS, INC. · Granted Oct 29, 2024 · Expires Oct 24, 2044

    granted
  21. US 12129467

    Non-liposomal systems for nucleic acid delivery

    ARBUTUS BIOPHARMA CORPORATION · Granted Oct 29, 2024 · Expires Oct 24, 2044

    granted
  22. US 12129258

    Diaryl macrocyclic compound and pharmaceutical composition, and use thereof

    PrimeGene (Beijing) Co., Ltd. · Granted Oct 29, 2024 · Expires Oct 24, 2044

    granted
  23. US 12129288

    Polynucleotides heterodimers of soluble interferon receptors and uses thereof

    Sanabio, LLC · Granted Oct 29, 2024 · Expires Oct 24, 2044

    granted
  24. US 12128013

    Toxic aldehyde related diseases and treatment

    Aldeyra Therapeutics, Inc. · Granted Oct 29, 2024 · Expires Oct 24, 2044

    granted

Frequently asked questions

What patents are included in this directory?

We index 30,257 published US pharma-relevant patents filtered to CPC classes A61K and A61P, with assignee links to our company directory where a match exists.

How do I search for a patent?

Use the search box to match patent number, title, applicant name, or CPC classification (e.g. A61K). For cross-entity queries spanning news and drugs, use the global search.

How is this different from the patent intelligence dashboard?

The dashboard at /patents highlights expirations, recent grants, and assignee rankings. Browse is the full paginated directory with search — best for looking up a specific filing or applicant portfolio slice.